2 completed, 1 terminated. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow bazlitoran: new trials by email Literature Review of bazlitoran trials Research Report on bazlitoran
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401 IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly - Waldenstrom's Macroglobulinemia | Phase 1 / Phase 2 | Completed | Idera Pharmaceuticals, Inc. | 5 | 2014-11-01 | 2018-01-09 |
| Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation IMO-8400 - Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Completed | Idera Pharmaceuticals, Inc. | 6 | 2014-06-01 | 2017-12-12 |
| Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia IMO-8400 - Waldenstrom's Macroglobulinemia | Phase 1 / Phase 2 | Terminated | Idera Pharmaceuticals, Inc. | 31 | 2014-03-01 | 2019-09-10 |
Waldenstrom Macroglobulinemia (2) · Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1)
Idera Pharmaceuticals, Inc. (3)
United States (2)